Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Status:
Not yet recruiting
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
Hope Biosciences is conducting a research study of an investigational product called
allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for
patients hospitalized with COVID-19. The study purpose is to evaluate the safety and efficacy
of four IV infusions of either placebo or HB-adMSCs in subjects with or without
hydroxychloroquine and azithromycin treatment for patients hospitalized with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Hope Biosciences
Collaborators:
Advanced Diagnostics Healthcare Hope Biosciences Stem Cell Research Foundation